Weighing the Options: Considerations for Adjuvant CDK4/6 Inhibitor Selection in HR+ Breast Cancer
Caution is needed when extrapolating the results of the phase 3 NATALEE trial (NCT03701334) with adjuvant ribociclib (Kisqali) in hormone receptor (HR)–positive breast cancer in the absence of data definitively demonstrating the agent’s long-term efficacy …